Horizon Pharma Inc. (HZNP) Given a $26.00 Price Target at Goldman Sachs Group Inc.
Goldman Sachs Group Inc. set a $26.00 price target on Horizon Pharma Inc. (NASDAQ:HZNP) in a report released on Wednesday. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.
HZNP has been the topic of a number of other research reports. Guggenheim restated a buy rating and issued a $30.00 target price on shares of Horizon Pharma in a research note on Tuesday, August 23rd. Cowen and Company restated an outperform rating and issued a $42.00 target price on shares of Horizon Pharma in a research note on Monday, September 12th. Vetr upgraded Horizon Pharma from a buy rating to a strong-buy rating in a research note on Monday, October 3rd. Mizuho increased their price target on Horizon Pharma from $30.00 to $33.00 and gave the stock a buy rating in a research report on Tuesday, September 13th. Finally, Morgan Stanley reiterated a hold rating and set a $24.00 price target on shares of Horizon Pharma in a research report on Wednesday, September 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $29.92.
Horizon Pharma (NASDAQ:HZNP) traded up 2.43% during midday trading on Wednesday, hitting $18.10. The company had a trading volume of 2,026,880 shares. Horizon Pharma has a 52 week low of $12.86 and a 52 week high of $23.70. The stock’s market capitalization is $2.91 billion. The stock has a 50 day moving average price of $18.79 and a 200-day moving average price of $17.86.
Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The firm earned $257.40 million during the quarter, compared to analyst estimates of $235.43 million. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. The business’s revenue for the quarter was up 48.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.39 EPS. On average, equities analysts predict that Horizon Pharma will post $2.15 EPS for the current year.
In other news, EVP Jeffrey W. Sherman sold 2,900 shares of the stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total transaction of $58,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 2.10% of the company’s stock.
Institutional investors have recently modified their holdings of the company. FMR LLC raised its stake in shares of Horizon Pharma by 1.7% in the second quarter. FMR LLC now owns 23,353,416 shares of the biopharmaceutical company’s stock worth $384,631,000 after buying an additional 401,302 shares during the period. Deerfield Management Co. raised its position in Horizon Pharma by 17.6% in the first quarter. Deerfield Management Co. now owns 13,740,261 shares of the biopharmaceutical company’s stock worth $227,676,000 after buying an additional 2,055,460 shares during the period. Vanguard Group Inc. raised its position in Horizon Pharma by 7.5% in the second quarter. Vanguard Group Inc. now owns 10,569,177 shares of the biopharmaceutical company’s stock worth $174,074,000 after buying an additional 737,812 shares during the period. BlackRock Fund Advisors raised its position in Horizon Pharma by 127.3% in the second quarter. BlackRock Fund Advisors now owns 6,678,136 shares of the biopharmaceutical company’s stock worth $109,989,000 after buying an additional 3,740,449 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Horizon Pharma by 28.6% in the second quarter. JPMorgan Chase & Co. now owns 4,341,698 shares of the biopharmaceutical company’s stock worth $71,508,000 after buying an additional 964,505 shares during the period. 85.25% of the stock is currently owned by hedge funds and other institutional investors.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Stock Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related stocks with our FREE daily email newsletter.